Treatment of Acute Colitis
For hospitalized patients with acute severe ulcerative colitis, initiate intravenous corticosteroids (prednisolone or equivalent) as first-line therapy, and if no response occurs within 3-5 days, escalate to either infliximab or cyclosporine as rescue therapy. 1, 2
Initial Assessment and First-Line Treatment
When a patient presents with acute severe colitis, immediately:
- Start intravenous corticosteroids (prednisolone 40-60mg daily or equivalent) combined with 5-ASA therapy 2
- Exclude infections first: Test for Clostridioides difficile (82% adherence in recent audits) and cytomegalovirus (CMV), though CMV testing adherence remains suboptimal at 30-60% 3
- Initiate VTE prophylaxis - this is critically underutilized (only 43% adherence overall, though improving to 75% post-guideline) despite high thrombotic risk 3
- Obtain gastroenterology consultation (occurs in 98% of cases) 3
The corticosteroid trial should last 3-5 days maximum - continuing beyond 7 days in non-responders is ineffective and delays definitive treatment 1.
Adjunctive Antibiotics: Not Recommended
Do not routinely add antibiotics unless there is documented gastrointestinal or extra-intestinal infection. Four RCTs demonstrated no benefit for adjunctive antibiotics in reducing colectomy risk (RR 0.79,95% CI 0.46-1.35), and after excluding questionable studies, the effect was essentially null (RR 0.95) 1.
Rescue Therapy for Steroid-Refractory Disease
If patients fail to respond to intravenous corticosteroids within 3-5 days:
Choose either infliximab OR cyclosporine - they are equally effective with no significant difference in short-term colectomy rates (RR 1.00,95% CI 0.72-1.40) or long-term outcomes (5-year colectomy-free survival ~61-65% for both) 1.
Practical Selection Between Rescue Agents:
Infliximab: Preferred for less severe cases, patients already on or planned for immunosuppressants (azathioprine/6-MP), and when maintenance therapy is anticipated. Allows for "bridge" to immunosuppressant action. Consider accelerated/intensified dosing in patients with high inflammatory burden or hypoalbuminemia 4, 5
Cyclosporine (2-4mg/kg/day IV): Reserved for more severe cases with imminent colectomy risk due to faster onset of action and short half-life. The 2mg/kg dose is comparable to 4mg/kg with potentially better safety profile 1, 5
Emerging Options:
Recent evidence suggests tofacitinib as adjunct to IV corticosteroids improves short-term response rates, while upadacitinib shows promise as salvage when corticosteroids and infliximab fail 4. However, these are not yet standard guideline recommendations.
Surgical Consultation and Timing
- Obtain colorectal surgery consultation early (currently only 30% adherence) 3
- Proceed to colectomy if no response after 5-7 days of rescue therapy, or immediately for complications (toxic megacolon, perforation, profuse hemorrhage) 5
- Colectomy rate is approximately 16-18% in contemporary series 3
Critical Pitfalls to Avoid:
- Prolonging ineffective corticosteroid therapy beyond 5-7 days - this delays rescue therapy and increases complications
- Inadequate VTE prophylaxis - remains dangerously underutilized despite high thrombotic risk
- Missing CMV infection - test before escalating immunosuppression
- Delaying surgical consultation - early involvement improves outcomes when medical therapy fails
Maintenance After Successful Rescue
Patients responding to rescue therapy should transition to maintenance with azathioprine/6-MP, continuing the biologic if infliximab was used. Note that 45.7% of cyclosporine-treated patients ultimately required infliximab within one year 1.